Healthcare provider profile · identity verified

Sadia A Jama, MD

Internal Medicine · SAINT PAUL, MN · NPI 1275742199

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Omeprazole	Omeprazole	241	71
Amlodipine Besylate	Amlodipine Besylate	218	72
Atorvastatin Calcium	Atorvastatin Calcium	205	73
Gabapentin	Gabapentin	155	44
Losartan Potassium	Losartan Potassium	125	44
Albuterol Sulfate Hfa	Albuterol Sulfate	121	33
Metoprolol Succinate	Metoprolol Succinate	104	26
Metformin Hcl Er	Metformin Hcl	97	29
Metformin Hcl	Metformin Hcl	95	28
Lisinopril	Lisinopril	90	19
Simvastatin	Simvastatin	86	22
Allopurinol	Allopurinol	79	22
Levothyroxine Sodium	Levothyroxine Sodium	79	20
Glipizide Er	Glipizide	77	24
Eliquis	Apixaban	62	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	60	17
Rosuvastatin Calcium	Rosuvastatin Calcium	60	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	59	21
Furosemide	Furosemide	58	21
Pantoprazole Sodium	Pantoprazole Sodium	52	19
Pregabalin	Pregabalin	49	14
Tradjenta	Linagliptin	49	13
Mirtazapine	Mirtazapine	43	suppressed
Pravastatin Sodium	Pravastatin Sodium	43	13
Warfarin Sodium	Warfarin Sodium	43	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	38	11
Jardiance	Empagliflozin	36	12
Tramadol Hcl	Tramadol Hcl	36	11
Famotidine	Famotidine	35	suppressed
Trazodone Hcl	Trazodone Hcl	35	11
Tizanidine Hcl	Tizanidine Hcl	34	suppressed
Fluticasone Propionate	Fluticasone Propionate	32	15
Januvia	Sitagliptin Phosphate	32	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	32	11
Carvedilol	Carvedilol	30	suppressed
Ozempic	Semaglutide	30	suppressed
Potassium Chloride	Potassium Chloride	30	11
Hydrocortisone	Hydrocortisone	29	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	28	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	28	suppressed
Xarelto	Rivaroxaban	27	suppressed
Duloxetine Hcl	Duloxetine Hcl	25	suppressed
Ventolin Hfa	Albuterol Sulfate	25	11
Myrbetriq	Mirabegron	23	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	22	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	22	suppressed
Spironolactone	Spironolactone	20	suppressed
Alendronate Sodium	Alendronate Sodium	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Linzess	Linaclotide	19	suppressed
Azithromycin	Azithromycin	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	13
Atenolol	Atenolol	16	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	11
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Clopidogrel	Clopidogrel Bisulfate	15	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Naproxen	Naproxen	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	14	suppressed
Cephalexin	Cephalexin	13	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	13	suppressed
Montelukast Sodium	Montelukast Sodium	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Glipizide	Glipizide	12	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Easy Touch Pen Needle	Pen Needle, Diabetic	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Sertraline Hcl	Sertraline Hcl	11	suppressed
Sulindac	Sulindac	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error